1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Vital Signs - Healthcare News - The Analyst's Perspect March 2014 Issue

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gilead's Sovaldi, Sony's genomic partnership with Illumina, and Craig Venter’s latest venture, Human Longevity, Inc.


LIFE SCIENCES


A panel of experts convened in San Francisco, Calif., to discuss the cost-effectiveness of Sovaldi, Gilead’s breakthrough therapy for the chronic hepatitis C infection (CHC). Sovaldi has been priced at $1,000 per pill, translating to a total cost of $84,000 for a 12-week treatment course. Some patients with a tougher-to-treat viral strain will need a 24-week course, with a price tag of $168,000. The expert panel concluded that, although this new drug is an important breakthrough in the treatment of CHC, the benefit does not outweigh the cost for all patients, nor would the healthcare system be able to support coverage for all CHC patients. Thus, many managed care organizations may need to restrict this drug to only the sickest patients who have tried and failed cheaper standard therapies.


The Analyst’s Perspective by Debbie Toscano, Senior Industry Analyst, Life Sciences

Development of better antiviral drugs to fight CHC is one of the most competitive areas in the pharmaceutical industry. The need for better treatments is high due to the growing number of infected people developing liver damage as the population ages, modest cure rate of available treatments, and no preventative vaccine for this highly transmissible virus. Since most people infected with hepatitis C virus (HCV) are not aware that they are infected or even at risk of infection, the US Preventive Services Task Force has recently recommended that all people born between 1945 and 1956 receive a one-time screening, an action with the potential to increase the treatable population even more.

Table Of Contents

Vital Signs - Healthcare News - The Analyst's Perspect March 2014 Issue
Table of Contents

Premium Price Tag of First-in-Class Sovaldi May Impede Patient Access 2
Sony Enters Genome Market, Teams Up with Illumina, M3 3
Craig Venter's Latest Genomic Startup Launches with Lofty Goals 4

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.